Concepedia

Angela Worth

AW

Statistics

Publications

7

Citations

476

H-Index

7

Active since

2010

Affiliations

Gilead Sciences (United States)(Current)

Angela Worth is an author at Gilead Sciences (United States) specializing in pharmacology, viral hepatitis, and hepatitis c virus resistance.

ORCID

Publications per year

2010–2018

7

Publications

7

Characterization of Hepatitis C Virus Resistance from a Multiple-Dose Clinical Trial of the Novel NS5A Inhibitor GS-5885

Kelly A. Wong, Angela Worth, Ross Martin et al. · Antimicrobial Agents and Chemotherapy · 2013 · 95 citations · Full text

, , +17

Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein

Eric Lawitz, Hadas Dvory‐Sobol, Brian Doehle et al. · Antimicrobial Agents and Chemotherapy · 2016 · 84 citations · Full text

, , +17

Cytochrome P450 3A Induction Predicts P‐glycoprotein Induction; Part 1: Establishing Induction Relationships Using Ascending Dose Rifampin

Justin D. Lutz, Brian J. Kirby, Lu Wang et al. · Clinical Pharmacology & Therapeutics · 2018 · 81 citations · Full text

, , +15

Susceptibility of Treatment-Naive Hepatitis C Virus (HCV) Clinical Isolates to HCV Protease Inhibitors

Andrew Bae, Siu-Chi Chang Sun, Xiaoping Qi et al. · Antimicrobial Agents and Chemotherapy · 2010 · 76 citations

, , +17

Cytochrome P450 3A Induction Predicts P‐glycoprotein Induction; Part 2: Prediction of Decreased Substrate Exposure After Rifabutin or Carbamazepine

Justin D. Lutz, Brian J. Kirby, Lu Wang et al. · Clinical Pharmacology & Therapeutics · 2018 · 75 citations · Full text

, , +17

1–5 of 7